These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28341596)

  • 1. Application of an NLME-Stochastic Deconvolution Approach to Level A IVIVC Modeling.
    Kakhi M; Suarez-Sharp S; Shepard T; Chittenden J
    J Pharm Sci; 2017 Jul; 106(7):1905-1916. PubMed ID: 28341596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling of pharmacokinetic systems using stochastic deconvolution.
    Kakhi M; Chittenden J
    J Pharm Sci; 2013 Dec; 102(12):4433-43. PubMed ID: 24174399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.
    Kesisoglou F; Xia B; Agrawal NG
    AAPS J; 2015 Nov; 17(6):1492-500. PubMed ID: 26290380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stochastic nonlinear mixed effects: a metformin case study.
    Matzuka B; Chittenden J; Monteleone J; Tran H
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):85-98. PubMed ID: 26585899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of level A in vitro-in vivo correlations for an extended-release formulation with limited bioavailability.
    Kakhi M; Marroum P; Chittenden J
    Biopharm Drug Dispos; 2013 Jul; 34(5):262-77. PubMed ID: 23097186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
    Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
    J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions.
    Margolskee A; Darwich AS; Galetin A; Rostami-Hodjegan A; Aarons L
    AAPS J; 2016 Mar; 18(2):321-32. PubMed ID: 26667356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convolution-based approaches for in vivo-in vitro correlation modeling.
    Gillespie WR
    Adv Exp Med Biol; 1997; 423():53-65. PubMed ID: 9269483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel extended IVIVC combined with DoE to predict pharmacokinetics from formulation compositions.
    Lim JY; Kim TH; Song CH; Kim DH; Shin BS; Shin S
    J Control Release; 2022 Mar; 343():443-456. PubMed ID: 35124130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exact Gradients Improve Parameter Estimation in Nonlinear Mixed Effects Models with Stochastic Dynamics.
    Olafsdottir HK; Leander J; Almquist J; Jirstrand M
    AAPS J; 2018 Aug; 20(5):88. PubMed ID: 30069613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Alternative Population Modeling Approaches for Implementing a Level A IVIVC and for Assessing the Time-Scaling Factor Using Deconvolution and Convolution-Based Methods.
    Gomeni R; Bressolle-Gomeni F
    AAPS J; 2020 Apr; 22(3):67. PubMed ID: 32297044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five modified numerical deconvolution methods for biopharmaceutics and pharmacokinetics studies.
    Yu Z; Schwartz JB; Sugita ET; Foehl HC
    Biopharm Drug Dispos; 1996 Aug; 17(6):521-40. PubMed ID: 8866043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specifications.
    Modi NB; Lam A; Lindemulder E; Wang B; Gupta SK
    Biopharm Drug Dispos; 2000 Nov; 21(8):321-6. PubMed ID: 11514951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of in vitro-in vivo correlation for extended-release niacin after administration of hypromellose-based matrix formulations to healthy volunteers.
    Kesisoglou F; Rossenu S; Farrell C; Van Den Heuvel M; Prohn M; Fitzpatrick S; De Kam PJ; Vargo R
    J Pharm Sci; 2014 Nov; 103(11):3713-3723. PubMed ID: 25256703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.
    Stillhart C; Pepin X; Tistaert C; Good D; Van Den Bergh A; Parrott N; Kesisoglou F
    AAPS J; 2019 Jan; 21(2):19. PubMed ID: 30673891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian knowledge integration for an in vitro-in vivo correlation model.
    Erhardt EM; Ursino M; Biewenga J; Jacobs T; Gasparini M
    Biom J; 2019 Sep; 61(5):1104-1119. PubMed ID: 30259557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convolution- and Deconvolution-Based Approaches for Prediction of Pharmacokinetic Parameters of Diltiazem Extended-Release Products in Flow-Through Cell Dissolution Tester.
    Taha NF; Emara LH
    AAPS PharmSciTech; 2022 Jul; 23(6):202. PubMed ID: 35882726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers.
    Balan G; Timmins P; Greene DS; Marathe PH
    J Pharm Sci; 2001 Aug; 90(8):1176-85. PubMed ID: 11536222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.